{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:06:07Z","timestamp":1790690767502,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100260","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:22:27Z","timestamp":1782382947000},"page":"100260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4887-5960","authenticated-orcid":false,"given":"Joanne E.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5368-8391","authenticated-orcid":false,"given":"Lina H. H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Ludford-Menting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6707-0421","authenticated-orcid":false,"given":"Nicholas","family":"Holzwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-4675","authenticated-orcid":false,"given":"Sasanka M.","family":"Handunnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-0215","authenticated-orcid":false,"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7329-6605","authenticated-orcid":false,"given":"David S.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-8934","authenticated-orcid":false,"given":"Rachel M.","family":"Koldej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bneo.2026.100260_bib1","series-title":"Haematolymphoid Tumours","year":"2024"},{"issue":"10","key":"10.1016\/j.bneo.2026.100260_bib2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/ajh.27058","article-title":"Marginal zone lymphoma: 2023 update on diagnosis and management","volume":"98","author":"Cheah","year":"2023","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.bneo.2026.100260_bib3","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2010-07-299321","article-title":"Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL","volume":"117","author":"Christopoulos","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100260_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1309\/AJCPPHKGYYGGL39C","article-title":"High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma\/chronic lymphocytic leukemia","volume":"132","author":"M'Hidi","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100260_bib5","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/leu.2008.82","article-title":"The peripheral helper T-cell repertoire in untreated indolent B-cell lymphomas: evidence for antigen-driven lymphomagenesis","volume":"22","author":"Christopoulos","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2026.100260_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-026-04404-6","article-title":"Mucosa-associated lymphoid tissue lymphoma with monoclonal T-cell expansion","author":"Jiang","year":"2026","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.bneo.2026.100260_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1393599","article-title":"B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity","volume":"7","author":"McKee","year":"2018","journal-title":"Oncoimmunology"},{"issue":"22","key":"10.1016\/j.bneo.2026.100260_bib8","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis","volume":"4","author":"Noy","year":"2020","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.bneo.2026.100260_bib9","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bneo.2026.100260_bib10","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/bloodadvances.2025016646","article-title":"Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma","volume":"10","author":"Handunnetti","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2026.100260_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.749094","article-title":"Venetoclax or ruxolitinib in pre-transplant conditioning lowers the engraftment barrier by different mechanisms in allogeneic stem cell transplant recipients","volume":"12","author":"Davis","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100260_bib12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1084\/jem.20160869","article-title":"Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival","volume":"214","author":"Viant","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.bneo.2026.100260_bib13","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1038\/ncomms5539","article-title":"Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells","volume":"5","author":"Sathe","year":"2014","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.bneo.2026.100260_bib14","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ni1487","article-title":"Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1","volume":"8","author":"Huntington","year":"2007","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100260_bib15","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/bloodadvances.2022008221","article-title":"Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells","volume":"7","author":"Teh","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2026.100260_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","article-title":"Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence","volume":"19","author":"Davis","year":"2021","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.bneo.2026.100260_bib17","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bneo.2026.100260_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk Res"},{"issue":"19","key":"10.1016\/j.bneo.2026.100260_bib19","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1182\/bloodadvances.2020002810","article-title":"Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy","volume":"4","author":"Davis","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bneo.2026.100260_bib20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2024015487","article-title":"Nivolumab and rituximab in treatment-naive follicular lymphoma: the phase 2 1st FLOR study","volume":"9","author":"Barraclough","year":"2025","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.bneo.2026.100260_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100260_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107458","article-title":"The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells","volume":"209","author":"Zhang","year":"2024","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.bneo.2026.100260_bib23","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.3324\/haematol.2019.220590","article-title":"Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma","volume":"105","author":"Flinsenberg","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bneo.2026.100260_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100260_bib25","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2024-193022","article-title":"Mosunetuzumab with response-driven lenalidomide augmentation as first-line therapy for symptomatic follicular or marginal zone lymphoma: interim analysis of a multi-center phase 2 study","volume":"144","author":"Olszewski","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100260_bib26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2024-200190","article-title":"Efficacy and safety of odronextamab in relapsed\/refractory marginal zone lymphoma (R\/R MZL): data from the R\/R MZL cohort in the ELM-2 study","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.bneo.2026.100260_bib27","article-title":"Marginal zone lymphoma: treatment update with a focus on systemic approaches","volume":"43","author":"Smith","year":"2025","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2026.100260_bib28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/bloodadvances.2025018137","article-title":"Ibrutinib exposure correlates with improved efficacy of CAR T-cells in patients with mantle cell lymphoma","volume":"10","author":"Darnell","year":"2025","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.bneo.2026.100260_bib29","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:16:15Z","timestamp":1790687775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000713"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100260","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100260"}}